Olink Holding AB (OLK)
23.01
-0.01
(-0.04%)
USD |
NASDAQ |
May 03, 16:00
22.99
-0.02
(-0.09%)
After-Hours: 20:00
Olink Free Cash Flow (Quarterly): -11.09M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -11.09M |
| September 30, 2023 | -21.91M |
| June 30, 2023 | -20.82M |
| March 31, 2023 | 2.568M |
| December 31, 2022 | -2.475M |
| September 30, 2022 | -22.19M |
| June 30, 2022 | -18.07M |
| March 31, 2022 | 4.119M |
| Date | Value |
|---|---|
| December 31, 2021 | -20.35M |
| September 30, 2021 | -17.31M |
| June 30, 2021 | -31.27M |
| March 31, 2021 | 0.439M |
| December 31, 2020 | -12.30M |
| September 30, 2020 | 0.522M |
| June 30, 2020 | -5.543M |
| March 31, 2020 | -0.722M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-31.27M
Minimum
Jun 2021
4.119M
Maximum
Mar 2022
-11.02M
Average
-11.69M
Median
Free Cash Flow (Quarterly) Benchmarks
| Thermo Fisher Scientific Inc | 904.00M |
| Abliva AB | -0.0813M |
| Karolinska Development AB | -0.6572M |
| Calliditas Therapeutics AB | -- |
| Oncopeptides AB | -4.947M |